-
-
-
-
-
-
-
AB Science reports phase 1 data for AB8939 plus venetoclax in AML
-
-
-
-
-
-
-
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
-
-
-
-
-
-
-
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
-
-
-
-
-
-
-
ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES FOURTH QUARTER RESULTS
-
-
-
-
-
-
-
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
-
-
-
-
-
-
-
AB Announces October 31, 2025 Assets Under Management
-
-
-
-
-
-
-
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
-
1,221,968 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

